Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beckman Coulter, Lumigen make it official

This article was originally published in The Gray Sheet

Executive Summary

Beckman Coulter gains access to Lumigen's technology for immunochemical and other high-sensitivity testing via its $185 mil. acquisition, expected to close by Nov. 1. Having partnered with Lumigen for more than 10 years, Beckman Coulter has already drawn from the company's well; Lumigen's chemiluminescent chemistry is the cornerstone of Beckman Coulter's Access family of immunoassay systems, the Oct. 2 release says...

You may also be interested in...



Beckman Coulter/NexGen

Beckman Coulter agrees to buy the remaining 80% of NexGen Diagnostics, which was spun off from Lumigen when Beckman Coulter bought Lumigen in 2006 (1"The Gray Sheet" Oct. 9, 2006, In Brief). NexGen's assets are intellectual property unrelated to current products. The technology will "simplify and automate certain types of immunodiagnostics and nucleic acid testing in remarkable ways, dramatically enhancing the performance of assays and accelerating turn-around time of test results," explains Richard Creager, VP of Beckman Coulter's Immunoassay Business Center. Beckman expects to take a charge of about $36 million for in-process R&D when the deal closes at the end of 2007

Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex

T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.

Drug Pricing ‘Not Appropriate Topic’ For WTO TRIPS Council

The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.

UsernamePublicRestriction

Register

MT024053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel